The Board of Directors of Bintai Kinden Corporation Berhad announced that Bintai Healthcare Sdn Bhd, a majority owned subsidiary of BKCB, has on 25 November 2020 entered into a Memorandum of Understanding with Generex and Nugenerex to further negotiate the terms and conditions wherein Generex and NuGenerex will be granting the licensing rights to BHSB to have the sole distribution rights to market and supply the synthetic peptide vaccine for SARS-CoV-2 ("Vaccine") to the Australia and New Zealand markets. The MOU shall come into agreement from the date of execution of the MOU and shall remain and valid till termination due to: forthwith by the company if there is non-conformance and/or non-performance by Generex under the Project; or if the other party ceases or threatens to cease to carry on its business or if a receiver, administrator or similar officer is appointed over all or part of the assets or undertaking of the other party. In the event of termination of the MOU, no Party shall have any claim against the other Party. The MOU shall be governed, construed, interpreted in accordance with the Laws of Malaysia
and subject to the jurisdiction of the courts in Malaysia.